interleukin 6 cytokine family signal transducerGenealiases: CD130 · CDW130 · GP130 · HIES4 · HIES4A · HIES4B
Q-omics provides the consensus-scored IL6ST profile across patient tissues and cancer cell-line models. IL6ST expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL6ST is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, IL6ST protein abundance shows 34,954 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where IL6ST shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL6ST — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL6ST survival associations across molecular data types. IL6ST RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL6ST RNA expression–survival associations across cancer types. High IL6ST expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRC, BRCA, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL6ST RNA expression.
This table summarizes IL6ST tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL6ST. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL6ST shows lower tumor expression in BLCA, LUAD, COAD, LUSC, UCEC and KICH. The BLCA box plot shows higher IL6ST RNA expression in normal versus tumor tissue (log2 FC = −2.091, t-test p < 0.001).
This table shows molecular features associated with IL6ST in patient tissues and cancer cell lines. In patient samples, IL6ST shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL6ST RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
